Barrett & Company Inc. grew its holdings in shares of Solventum Corporation (NYSE:SOLV – Free Report) by 206.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 398 shares of the company’s stock after purchasing an additional 268 shares during the quarter. Barrett & Company Inc.’s holdings in Solventum were worth $30,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Rossby Financial LCC acquired a new stake in shares of Solventum during the 1st quarter worth $25,000. Strengthening Families & Communities LLC increased its holdings in shares of Solventum by 376.8% during the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after buying an additional 260 shares during the last quarter. Hara Capital LLC acquired a new stake in shares of Solventum during the 1st quarter worth $38,000. Smartleaf Asset Management LLC increased its holdings in shares of Solventum by 193.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after buying an additional 352 shares during the last quarter. Finally, Costello Asset Management INC acquired a new stake in shares of Solventum during the 1st quarter worth $42,000.
Solventum Stock Down 0.8%
Shares of NYSE SOLV opened at $74.03 on Friday. The stock has a fifty day moving average price of $72.80 and a 200 day moving average price of $72.21. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The company has a market cap of $12.84 billion, a P/E ratio of 34.27, a P/E/G ratio of 3.03 and a beta of 0.50. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92.
Wall Street Analyst Weigh In
A number of analysts have recently commented on SOLV shares. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Zacks Research upgraded Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Jefferies Financial Group started coverage on Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target for the company. Wells Fargo & Company increased their price target on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a report on Monday, September 15th. Finally, Wall Street Zen downgraded Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $84.60.
Read Our Latest Analysis on Solventum
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Stories
- Five stocks we like better than Solventum
- Pros And Cons Of Monthly Dividend Stocks
- After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught?
- What is the NASDAQ Stock Exchange?
- Alphabet: After Its Best Quarter in Decades, Is It Time to Buy?
- What does consumer price index measure?
- Forget Airlines—These Trucking Stocks Are Shifting Into High Gear
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.